SEARCH

SEARCH BY CITATION

References

  • 1
    Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM, Gao F, Moyer LA et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999; 341: 556562.DOI: 10.1056/NEJM199908193410802
  • 2
    Kiyosawa K, Sodeyama T, Tanaka E, Gibo Y, Yoshizawa K, Nakano Y et al. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus. Hepatology 1990; 12: 671675.
  • 3
    Wright TL, Donegan E, Hsu HH, Ferrelle L, Lake JR, Kim M et al. Recurrent and acquired hepatitis C viral infection in liver transplant recipients. Gastroenterology 1992; 103: 317322.
  • 4
    Gane EJ, Portmann BC, Naoumov NV, Smith HM, Underhill JA, Donaldson PT et al. Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med 1996; 334: 815820.DOI: 10.1056/NEJM199603283341302
  • 5
    Sanchez-Fueyo A, Restrepo JC, Quinto L, Bruguera M, Grande L, Sanchez-Tapias JM et al. Impact of the recurrence of hepatitis C virus infection after liver transplantation on the long-term viability of the graft. Transplantation 2002; 73: 5663.DOI: 10.1097/00007890-200201150-00010
  • 6
    Berenguer M, Ferrell L, Watson J, Prieto M, Kim M, Rayon M et al. HCV-related fibrosis progression following liver transplantation: increase in recent years. J Hepatol 2000; 32: 673684.
  • 7
    Berenguer M, Prieto M, San Juan F, Rayon JM, Martinez F, Carrasco D et al. Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients. Hepatology 2002; 36: 202210.
  • 8
    Wali M, Harrison RF, Gow PJ, Mutimer D. Advancing donor liver age and rapid fibrosis progression following transplantation for hepatitis C. Gut 2002; 51: 248252.DOI: 10.1136/gut.51.2.248
  • 9
    Bizollon T, Palazzo U, Ducerf C, Chevallier M, Elliot M, Baulieux J et al. Pilot study of the combination of interferon and ribavirin as therapy of recurrent hepatitis C after liver transplantation. Hepatology 1997; 26: 500504.
  • 10
    Samuel D, Bizollon T, Feray C, Roche B, Ahmed SN, Lemonnier C et al. Interferon plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study. Gastroenterology 2003; 124: 642650.DOI: 10.1053/gast.2003.50095
  • 11
    Bizollon T, Ahmed SN, Radenne S, Chevallier M, Chevallier P, Parvaz P et al. Long term histological improvement and clearance of intrahepatic C virus RNA following sustained response to interferon-ribavirin combination therapy in liver transplanted patients with hepatitis C virus recurrence. Gut 2003; 52: 283287.
  • 12
    Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996; 24: 289293.
  • 13
    Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MER. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002; 122: 889896.
  • 14
    Berenguer M, Prieto M, San Juan F, Rayon JM, Martinez F, Carrasco D et al. Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients. Hepatology 2002; 36: 202210.
  • 15
    Neumann UP, Berg T, Bahra M, Puhl G, Guckelberger O, Langrehr Neuhaus P. Long-term outcome of liver transplants for chronic hepatitis 10-year follow-up. Transplantation 2004; 77: 226231.DOI: 10.1097/01.TP.0000101738.27552.9D
  • 16
    Kondo M, Tanaka K, Ikeda M, Arata S, Saito S, Sakaguchi T et al. Hepatic HCV-RNA as a predictor of outcome after interferon therapy in patients with chronic hepatitis C. J Gastroenterol Hepatol 1996; 11: 236240.
  • 17
    Shindo M, Arai K, Sokawa Y, Okuno T. Hepatic hepatitis C virus RNA as a predictor of a long-term response to interferon-alpha therapy. Ann Intern Med 1995; 122: 586591.
  • 18
    Marcellin P, Boyer N, Gervais A, Martinot M, Pouteau M, Castelnau C et al. Long term histological improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained virological response to interferon-alpha therapy. Ann Int Med 1997; 127: 875881.
  • 19
    Chemello L, Cavalletto L, Casarin C, Bonetti P, Bernardinello E, Pontisso P et al. Persistent hepatitis C viremia predicts late relapse after sustained response to interferon-alpha in chronic. Ann Intern Med 1996; 124: 10581060.
  • 20
    Sim H, Yim C, Krajden M, Heathcote J. Durability of serological remission in chronic hepatitis C treated with interferon-alpha-2b. Am J Gastroenterol 1998; 93: 3943.DOI: 10.1111/j.1572-0241.1998.039_c.x
    Direct Link:
  • 21
    Abdelmalek M, Firpi R, Soldevila-Pico C, Reed A, Hemming A, Liu C et al. Sustained virological response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C. Liver Transpl 2004; 10: 199207.DOI: 10.1002/lt.20074
  • 22
    Bizollon T, Adham M, Pradat P, Chevallier M, Ducerf C, Baulieux J et al Triple antiviral therapy with amantadine for IFN-ribavirin non-responders with recurrent post transplantation hepatitis C. Transplantation 2005; 79: 325329.
  • 23
    McHutchison JG, Poynard T. Combination therapy with interferon plus ribavirin for the initial treatment of chronic hepatitis C. Semin Liver Dis 1999; 19(Suppl 1): 5765.
  • 24
    Poynard T, McHutchison J, Manns M, Trepo C, Lindsay K, Goodman Z et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002; 122: 13031313.